Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 12, 2014 - Issue 2
Submit an article Journal homepage
288
Views
6
CrossRef citations to date
0
Altmetric
Themed Article: Disorders of the Myocardium - Reviews

Fibrinolytic therapy in patients with ST-elevation myocardial infarction

Amirreza SolhpourDepartment of Cardiology, University of Texas Health Science Center at Houston and Memorial Hermann Heart and Vascular Institute, Houston, 77030-1503 TX, USACorrespondence[email protected]
&
Syed W YusufDepartment of Cardiology, MD Anderson Cancer Center, Houston, TX, USA
Pages 201-215 | Published online: 11 Dec 2013

References

  • Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation 127(1), e6–e245 (2013).
  • Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348(9030), 771–775 (1996).
  • O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127(4), e362–e425 (2013).
  • Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol 58(24), e44–e122 (2011).
  • Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur. Heart. J. 31(20), 2501–2555 (2010).
  • Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 278(23), 2093–2098 (1997).
  • Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351), 13–20 (2003).
  • Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33(20), 2569–2619 (2012).
  • Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N. Engl. J. Med. 328(10), 680–684 (1993).
  • Armstrong PW, Boden WE. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann. Intern. Med. 155(6), 389–391 (2011).
  • Steg PG, Bonnefoy E, Chabaud S et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 108(23), 2851–2856 (2003).
  • Widimsky P, Budesinsky T, Vorac D et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur. Heart J. 24(1), 94–104 (2003).
  • Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am. J. Cardiol. 92(7), 824–826 (2003).
  • Roe MT, Messenger JC, Weintraub WS et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J. Am. Coll. Cardiol. 56(4), 254–263 (2010).
  • Terkelsen CJ, Sorensen JT, Maeng M et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 304(7), 763–771 (2010).
  • Pinto DS, Frederick PD, Chakrabarti AK et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 124(23), 2512–2521 (2011).
  • McNamara RL, Herrin J, Bradley EH et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J. Am. Coll. Cardiol. 47(1), 45–51 (2006).
  • De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109(10), 1223–1225 (2004).
  • Stone GW, Cox D, Garcia E et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104(6), 636–641 (2001).
  • Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation 119(9), 1293–1303 (2009).
  • Tillett WS, Garner RL. The Fibrinolytic Activity of Hemolytic Streptococci. J. Exp. Med. 58(4), 485–502 (1933).
  • Sherry S, Fletcher AP, Alkajersig N, Smyrniotis FE. An approach to intravascular fibrinolysis in man. Trans. Assoc. Am. Physicians 70, 288–295, discussion 295–286 (1957).
  • Streptokinase in recent myocardial infarction: a controlled multicentre trial. European working party. Br. Med. J. 3(5770), 325–331 (1971).
  • Markis JE, Malagold M, Parker JA et al. Myocardial salvage after intracoronary thrombolysis with streptokinase in acute myocardial infarction. N. Engl. J. Med. 305(14), 777–782 (1981).
  • Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem. 256(13), 7035–7041 (1981).
  • Van de Werf F, Ludbrook PA, Bergmann SR et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N. Engl. J. Med. 310(10), 609–613 (1984).
  • Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet 1(8478), 397–402 (1986).
  • Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group. Lancet 1(8585), 545–549 (1988).
  • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2(8607), 349–360 (1988).
  • Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 343(8893), 311–322 (1994).
  • GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet 336(8707), 65–71 (1990).
  • ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 339(8796), 753–770 (1992).
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N. Engl. J. Med. 329(10), 673–682 (1993).
  • The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N. Engl. J. Med. 329(22), 1615–1622 (1993).
  • Ridker PM, O’Donnell C, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann. Intern. Med. 119(6), 530–532 (1993).
  • Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Ann. Intern. Med. 120(10), 876–881, discussion 882–875 (1994).
  • Ridker PM, O’Donnell CJ, Marder VJ, Hennekens CH. A response to “holding GUSTO up to the light.” Ann. Intern. Med. 120, 882–885 (1994).
  • Fuster V. Coronary thrombolysis--a perspective for the practicing physician. N. Engl. J. Med. 329(10), 723–725 (1993).
  • Hennekens CH. Thrombolytic therapy: pre- and post-GISSI-2, ISIS-3, and GUSTO-1. Clin. Cardiol. 17( 1 Suppl. 1), I15–I17 (1994).
  • Sleight P. Thrombolysis after GUSTO: a European perspective. J. Myocard. Ischemia 5, 25–30 (1993).
  • Rapaport E. GUSTO: assessment of the preliminary results. J. Myocard. Ischemia 5, 15–24 (1993).
  • Conti RC. Myocardial infarction, thrombolytic therapy, and economics. Clin. Cardiol. 16(9), 635 (1993).
  • Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Study Protocol. 21 March (1991).
  • Van De Werf F, Adgey J, Ardissino D et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354(9180), 716–722 (1999).
  • A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N. Engl. J. Med. 337(16), 1118–1123 (1997).
  • Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur. Heart J. 21(24), 2005–2013 (2000).
  • Taher T, Fu Y, Wagner GS et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J. Am. Coll. Cardiol. 44(1), 38–43 (2004).
  • Westerhout CM, Bonnefoy E, Welsh RC, Steg PG, Boutitie F, Armstrong PW. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am. Heart J. 161(2), 283–290 (2011).
  • Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N. Engl. J. Med. 368(15), 1379–1387 (2013).
  • Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 283(20), 2686–2692 (2000).
  • Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. BMJ 305(6853), 548–553 (1992).
  • Kalla K, Christ G, Karnik R et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 113(20), 2398–2405 (2006).
  • Bonnefoy E, Lapostolle F, Leizorovicz A et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 360(9336), 825–829 (2002).
  • Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 111(6), 761–767 (2005).
  • Kereiakes DJ, Gibler WB, Martin LH, Pieper KS, Anderson LC. Relative importance of emergency medical system transport and the prehospital electrocardiogram on reducing hospital time delay to therapy for acute myocardial infarction: a preliminary report from the Cincinnati Heart Project. Am. Heart J. 123(4 Pt 1), 835–840 (1992).
  • Canto JG, Rogers WJ, Bowlby LJ, French WJ, Pearce DJ, Weaver WD. The prehospital electrocardiogram in acute myocardial infarction: is its full potential being realized? National Registry of Myocardial Infarction 2 Investigators. J. Am. Coll. Cardiol. 29(3), 498–505 (1997).
  • Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N. Engl. J. Med. 336(12), 847–860 (1997).
  • Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N. Engl. J. Med. 329(6), 383–389 (1993).
  • Barbash GI, Roth A, Hod H et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. Am. J. Cardiol. 66(3), 261–266 (1990).
  • Castaigne AD, Herve C, Duval-Moulin AM et al. Prehospital use of APSAC: results of a placebo-controlled study. Am. J. Cardiol. 64(2), 30A–33A, discussion 41A–42A (1989).
  • Danchin N, Blanchard D, Steg PG et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 110(14), 1909–1915 (2004).
  • McAleer B, Ruane B, Burke E et al. Prehospital thrombolysis in a rural community: short- and long-term survival. Cardiovasc. Drugs Ther. 6(4), 369–372 (1992).
  • McNeill AJ, Cunningham SR, Flannery DJ et al. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. Br. Heart J. 61(4), 316–321 (1989).
  • Morrow DA, Antman EM, Sayah A et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J. Am. Coll. Cardiol. 40(1), 71–77 (2002).
  • Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J. Am. Coll. Cardiol. 23(1), 1–5 (1994).
  • Roth A, Barbash GI, Hod H et al. Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. J. Am. Coll. Cardiol. 15(5), 932–936 (1990).
  • Schofer J, Buttner J, Geng G et al. Prehospital thrombolysis in acute myocardial infarction. Am. J. Cardiol. 66(20), 1429–1433 (1990).
  • Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108(2), 135–142 (2003).
  • Weaver WD, Cerqueira M, Hallstrom AP et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 270(10), 1211–1216 (1993).
  • Bjorklund E, Stenestrand U, Lindback J, Svensson L, Wallentin L, Lindahl B. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur. Heart J. 27(10), 1146–1152 (2006).
  • Denktas AE, Athar H, Henry TD et al. Reduced-dose fibrinolytic acceleration of ST-segment elevation myocardial infarction treatment coupled with urgent percutaneous coronary intervention compared to primary percutaneous coronary intervention alone results of the AMICO (Alliance for Myocardial Infarction Care Optimization) Registry. JACC Cardiovasc. Interv. 1(5), 504–510 (2008).
  • Bhatt NS, Solhpour A, Balan P et al. Comparison of in-hospital outcomes with low-dose fibrinolytic therapy followed by urgent percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial infarction. Am. J. Cardiol. 111(11), 1576–1579 (2013).
  • Smalling RW, Giesler GM, Julapalli VR et al. Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous coronary intervention reduces time to reperfusion and improves angiographic perfusion score compared with prehospital fibrinolysis alone or primary percutaneous coronary intervention: results of the PATCAR Pilot Trial. J. Am. Coll. Cardiol. 50(16), 1612–1614 (2007).
  • Weinstock BS. Contemporary management of ST elevation myocardial infarction. Semin. Thromb. Hemost. 30(6), 673–681 (2004).
  • Chew DP, Aylward P, White HD. Facilitated percutaneous coronary intervention: is this strategy ready for implementation? Curr. Cardiol. Rep. 7(4), 235–241 (2005).
  • Gore JM, Sloan M, Price TR et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II , pilot and clinical trial. Circulation 83(2), 448–459 (1991).
  • Cannon CP, Gibson CM, McCabe CH et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 98(25), 2805–2814 (1998).
  • Menon V, Harrington RA, Hochman JS et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126( 3 Suppl.), 549S–575S (2004).
  • Vorchheimer D, Baruch L, Thompson T, Kukin M. North American vs. non-North American streptokinase use in GUSTO-I: impact of protocol deviation on mortality benefit of TPA [abstract]. Circulation 96( Suppl. I), I–535 (1997).
  • Seyedroudbari A, Kessler ER, Mooss AN, Wundeman RL, Bala M, Hilleman DE. Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA. J. Thromb. Thrombolysis 9(3), 303–308 (2000).
  • Coulter S, McCabe CH, Giugliano RP. Dosing errors and outcomes in patients receiving single-bolus compared with bolus + infusion thrombolytic regimens: an InTIME-II study [abstract]. Circulation 100( Suppl. I), 1 (1999).
  • Murphy SA, Gibson CM, Van de Werf F, McCabe CH, Cannon CP. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am. J. Cardiol. 90(1), 51–54 (2002).
  • Richards CF, Cannon CP. Reducing medication errors: potential benefits of bolus thrombolytic agents. Acad. Emerg. Med. 7(11), 1285–1289 (2000).
  • Cannon CP. Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am. J. Cardiol. 85(8A), 17C–22C (2000).
  • Coe TR, Halkes M, Houghton K, Jefferson D. The accuracy of visual estimation of weight and height in pre-operative supine patients. Anaesthesia 54(6), 582–586 (1999).
  • Hall WL, 2nd, Larkin GL, Trujillo MJ, Hinds JL, Delaney KA. Errors in weight estimation in the emergency department: comparing performance by providers and patients. J. Emerg. Med. 27(3), 219–224 (2004).
  • Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 346(8971), 329–336 (1995).
  • Modi NB, Fox NL, Clow FW et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J. Clin. Pharmacol. 40(5), 508–515 (2000).
  • Wijeysundera HC, You JJ, Nallamothu BK, Krumholz HM, Cantor WJ, Ko DT. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: a meta-analysis of contemporary randomized controlled trials. Am. Heart. J. 156(3), 564–572, 572 e561–562 (2008).
  • Borgia F, Goodman SG, Halvorsen S et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur. Heart. J. 31(17), 2156–2169 (2010).
  • Gurbel PA, Serebruany VL, Shustov AR et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 h of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J. Am. Coll. Cardiol. 31(7), 1466–1473 (1998).
  • Califf RM, Topol EJ, George BS et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am. J. Med. 85(3), 353–359 (1988).
  • Topol EJ, Califf RM, George BS et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N. Engl. J. Med. 317(10), 581–588 (1987).
  • Dauerman HL, Prpic R, Andreou C, Vu MA, Popma JJ. Angiographic and clinical outcomes after rescue coronary stenting. Catheter. Cardiovasc. Interv. 50(3), 269–275 (2000).
  • Schomig A, Ndrepepa G, Mehilli J et al. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 44(10), 2073–2079 (2004).
  • Fernandez-Aviles F, Alonso JJ, Castro-Beiras A et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 364(9439), 1045–1053 (2004).
  • Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J. Am. Coll. Cardiol. 55(2), 102–110 (2010).
  • Di Mario C, Dudek D, Piscione F et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 371(9612), 559–568 (2008).
  • Cantor WJ, Fitchett D, Borgundvaag B et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N. Engl. J. Med. 360(26), 2705–2718 (2009).
  • Gore JM, Granger CB, Simoons ML et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 92(10), 2811–2818 (1995).
  • Van de Werf F, Barron HV, Armstrong PW et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur. Heart J. 22(24), 2253–2261 (2001).
  • Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286(6), 708–713 (2001).
  • Alexander KP, Newby LK, Armstrong PW et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115(19), 2570–2589 (2007).
  • Bueno H, Betriu A, Heras M et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur. Heart J. 32(1), 51–60 (2011).
  • Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 101(19), 2239–2246 (2000).
  • Stenestrand U, Wallentin L. Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch. Intern. Med. 163(8), 965–971 (2003).
  • Bradley EH, Nallamothu BK, Herrin J et al. National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance. J. Am. Coll. Cardiol. 54(25), 2423–2429 (2009).
  • Wang TY, Nallamothu BK, Krumholz HM et al. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA 305(24), 2540–2547 (2011).
  • Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 55(23), 2556–2566 (2010).
  • Dauerman HL, Rao SV, Resnic FS, Applegate RJ. Bleeding avoidance strategies. Consensus and controversy. J. Am. Coll. Cardiol. 58(1), 1–10 (2011).
  • Mehran R, Lansky AJ, Witzenbichler B et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374(9696), 1149–1159 (2009).
  • Jolly SS, Yusuf S, Cairns J et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 377(9775), 1409–1420 (2011).
  • Scuffham PA, Tippett V. The cost-effectiveness of thrombolysis administered by paramedics. Curr. Med. Res. Opin. 24(7), 2045–2058 (2008).
  • Selmer R, Halvorsen S, Myhre KI, Wisloff TF, Kristiansen IS. Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction. Scand. Cardiovasc. J. 39(5), 276–285 (2005).
  • Bravo Vergel Y, Palmer S, Asseburg C et al. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart 93(10), 1238–1243 (2007).
  • Abdul-Rahman S, Nammas W, Gamal A, Adel A, Zaki T. Routine invasive versus ischemia-guided strategy in patients with acute inferior ST-elevation myocardial infarction who received fibrinolytic therapy: a prospective randomized controlled pilot trial. J. Invasive Cardiol. 23(8), 316–321 (2011).
  • Luepker RV, Raczynski JM, Osganian S et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA 284(1), 60–67 (2000).
  • Finnegan JR, Jr, Meischke H, Zapka JG et al. Patient delay in seeking care for heart attack symptoms: findings from focus groups conducted in five US regions. Prev. Med. 31(3), 205–213 (2000).
  • Bradley EH, Roumanis SA, Radford MJ et al. Achieving door-to-balloon times that meet quality guidelines: how do successful hospitals do it? J. Am. Coll. Cardiol. 46(7), 1236–1241 (2005).
  • Stone GW, Gersh BJ. Facilitated angioplasty: paradise lost. Lancet 367(9510), 543–546 (2006).
  • Curtis JP, Portnay EL, Wang Y et al. The pre-hospital electrocardiogram and time to reperfusion in patients with acute myocardial infarction, 2000–2002: findings from the National Registry of Myocardial Infarction-4. J. Am. Coll. Cardiol. 47(8), 1544–1552 (2006).
  • Nallamothu BK, Taheri PA, Barsan WG, Bates ER. Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States. Am. Heart J. 152(4), 613–618 (2006).
  • Kiernan TJ, Gersh BJ. Thrombolysis in acute myocardial infarction: current status. Med. Clin. North Am. 91(4), 617–637 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.